Related Experiment Video
Updated: May 31, 2026
06:12
Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition
Published on: March 3, 2023
The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice
Anthony J Courey1, Jeffrey C Horowitz, Kevin K Kim
1Division of Pulmonary and Critical Care Medicine. Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Blood
|July 8, 2011
Summary
The vitronectin-binding function of plasminogen activator inhibitor-1 (PAI-1) is key to worsening lung scarring. This finding was confirmed in animal models of pulmonary fibrosis, highlighting PAI-1's role in lung fibrogenesis.
Area of Science:
- Pulmonary Medicine
- Cell Biology
- Extracellular Matrix Biology
Background:
- Plasminogen activator inhibitor-1 (PAI-1) is elevated in pulmonary fibrosis lungs.
- PAI-1 has antiprotease and vitronectin-binding functions that may promote fibrosis.
Purpose of the Study:
- To determine which PAI-1 function, antiprotease or vitronectin-binding, is more critical in exacerbating lung fibrosis.
- To investigate the role of PAI-1 in lung fibrogenesis following injury.
Main Methods:
- Utilized a bleomycin-induced lung injury model in mice genetically deficient in PAI-1.
- Administered mutant PAI-1 proteins with either intact antiprotease or vitronectin-binding activity.
- Confirmed findings in genetically modified mice expressing mutant PAI-1 proteins.
Main Results:
- The vitronectin-binding capacity of PAI-1 was found to be the primary driver of exacerbated lung scarring.
- PAI-1's ability to potentiate fibrosis was directly linked to its vitronectin-binding function, not its antiprotease activity.
- Experimental data confirmed the critical role of PAI-1's vitronectin-binding function in bleomycin-induced lung fibrosis.
Conclusions:
- The vitronectin-binding function of PAI-1 is both necessary and sufficient for exacerbating lung fibrotic processes.
- Targeting PAI-1's vitronectin-binding interaction may represent a therapeutic strategy for pulmonary fibrosis.
- This study elucidates a specific mechanism by which PAI-1 contributes to lung scarring.
